	US 12,344,638 B2
	Functionalized UBX protein materials for enhanced purification of antibodies
Sarah E. Bondos, College Station, TX (US); and David W. Howell, College Station, TX (US)
Assigned to BONDWELL TECHNOLOGIES LP, College Station, TX (US)
Appl. No. 17/600,960
Filed by BONDWELL TECHNOLOGIES INC., College Station, TX (US)
PCT Filed Apr. 2, 2020, PCT No. PCT/US2020/026412 § 371(c)(1), (2) Date Oct. 1, 2021, PCT Pub. No. WO2020/206138, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/828,142, filed on Apr. 2, 2019.
Prior Publication US 2022/0251147 A1, Aug. 11, 2022
Int. Cl. C07K 14/31 (2006.01); C07K 1/22 (2006.01); C07K 14/435 (2006.01)

CPC C07K 14/31 (2013.01) [C07K 1/22 (2013.01); C07K 14/43563 (2013.01)]

9 Claims

1. A Ubx biomaterial comprising two or more self-assembled fusion proteins, wherein each fusion protein comprises at least one Ubx protein and an immunoglobulin binding protein, wherein the immunoglobulin binding protein comprises one or more monomeric domains of domain Z or an immunoglobulin binding functional variant thereof, wherein domain Z comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1, and wherein the immunoglobulin binding protein is linked to the N-terminus of the Ubx protein via a linker.